Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of CPT + thalidomide + dexamethasone versus thalidomide + dexamethasone in relapsed or refractory multiple myeloma
ChiCTR-TRC-11001625Phase 2Recruiting
- Sponsor
- Beijing Chaoyang Hospital
- Start
- Jan 2011
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of camptothecin in multiple myeloma (MM) (2 arms), sponsored by Beijing Chaoyang Hospital. Primary endpoint: Objective response rate. Started Jan 2011; status: recruiting.
02
Drugs
camptothecin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR-TRC-11001625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-11001625.